NF2 BioSolutions is breaking the research silos to cure NF2

2 Views

07/10/23

Please Donate at http://NF2BioSolutions.org/donate .NF2 BioSolutions, a patient led nonprofit, is breaking the silos by jumpstarting NF2 novel therapy research projects and by generating collaboration between top tier research centres. Dr Gary Brenner (Harvard School, Mass General Hospital) , Dr Joseph Kissil (Scripps Rewearch) and Dr Edgar Rodriguez (NF2 BioSolutions CSO) are talking about the role of NF2 BioSolutions and how it is important to support it. Please Donate at http://NF2BioSolutions.org/donate

We have four long term NF2 therapies approaches but they won't progress and succeed without your support. Be part of the solution, please donate at nf2biosolutions.org/donate or below click donate button. To know more, read carefully our 4 approaches:

Approach 1. Gene addition therapy (gene therapy) . At Nationwide Children Hospital (Columbus, Ohio), Gene Therapy Research Centre lab of Dr Meyer.
Through a vector(genetically modified virus), we introduce healthy NF2 genes, so these "working" NF2 gene will produce the merlin protein that is needed to signal the tumor to stop growing.

Approach 2. Gene replacement therapy (gene therapy). At UMASS Boston, at Dr Mueller lab with Dr Meijboom.
Through a vector(virus), we first silence the existing mutated NF2 gene so they stop producing toxic proteins and we add new healthy NF2 genes that will produce the merlin protein that is needed to stop the tumor growth. Vectors are being designed. Trial on NF2 mice did not started yet.

Approach 3. Suicide gene therapy (gene therapy). At Harvard Medical School/ Mass General Hospital, Boston, Dr Brenner’s lab.
Through a vector(virus) we introduce the ASC gene that promote cells death . The result will be a shrinkage of the tumor. Trial on mice have proven its efficacy. Now the project is ready to move to the next phase toxicology study and then trial.

Approach 4. Tumour-targeting bacteria therapy. At Harvard Medical School/ Mass General Hospital, Boston with Dr Mekalanos’s lab.
A genetically modified bacteria is introduced to kill the NF2 tumour cells via several mechanisms including direct killing, inducing anti-tumor immune response (immunotherapy) and inhibiting blood vessel formation. Bacterial cancer therapy has been proven safe and well tolerated in multiple clinical trials. For example it is the treatment of choice for the non-invasive bladder cancer with a 50% cure rate. Trial on mice have proven its efficacy. Work in progress to genetically modified the bacteria.